STOCK TITAN

Amylyx (NASDAQ: AMLX) director receives 24,372 stock options grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Amylyx Pharmaceuticals director Bernhardt G. Zeiher received a grant of 24,372 stock options. These options give the right to buy 24,372 shares of Amylyx common stock at an exercise price of $14.31 per share and expire on June 3, 2036.

According to the terms, the options vest in full on the earlier of June 4, 2027 or the date of the next annual meeting, as long as the director remains in continuous service with the company through that vesting date. After this grant, the director holds 24,372 derivative securities directly.

Positive

  • None.

Negative

  • None.
Insider Zeiher Bernhardt G
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 24,372 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 24,372 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 24,372 options Stock Option (right to buy) granted on June 4, 2026
Exercise price $14.31 per share Conversion or exercise price of granted options
Expiration date June 3, 2036 Option expiration for director grant
Post-grant derivative holdings 24,372 options Total shares underlying options following transaction
Vesting date trigger June 4, 2027 or next annual meeting Full vesting contingent on continuous service to vesting date
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 14.3100"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The shares subject to this option shall vest in full upon the earlier of"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-06-03T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
derivative securities financial
"derivativeTransactionCount: 1"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Zeiher Bernhardt G

(Last)(First)(Middle)
C/O AMYLYX PHARMACEUTICALS, INC.
55 CAMBRIDGE PARKWAY, SUITE 6W

(Street)
CAMBRIDGE MASSACHUSETTS 02142

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Amylyx Pharmaceuticals, Inc. [ AMLX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$14.3106/04/2026A24,372 (1)06/03/2036Common Stock24,372$024,372D
Explanation of Responses:
1. The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
/s/ Joshua B. Cohen, as Attorney in Fact06/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Amylyx (AMLX) director Bernhardt G. Zeiher receive in this Form 4?

Bernhardt G. Zeiher received a grant of 24,372 stock options to acquire Amylyx common shares at a set price. This is a compensation-related award, not an open-market purchase or sale, and represents his reported derivative holdings after the transaction.

What is the exercise price and expiration for the new Amylyx (AMLX) stock options?

The granted stock options have an exercise price of $14.31 per share and expire on June 3, 2036. This means the director can buy Amylyx common shares at $14.31 any time before that expiration date, once the options are vested.

When do Bernhardt G. Zeiher’s Amylyx (AMLX) options vest?

The options vest in full on the earlier of June 4, 2027 or the date of the next annual meeting. Vesting requires the director’s continuous service with Amylyx through that date, aligning the award with ongoing board participation.

Does this Amylyx (AMLX) Form 4 show any stock being bought or sold on the market?

No open-market buys or sells are reported; it only shows a grant of 24,372 stock options. The transaction is coded as an award acquisition, a common form of equity-based director compensation rather than a discretionary market trade.

How many Amylyx (AMLX) derivative securities does the director hold after this grant?

Following the option grant, the director is reported as holding 24,372 derivative securities directly. Each option corresponds to one underlying share of Amylyx common stock, giving him rights to purchase up to 24,372 shares upon exercise.